Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;17(1):5.
doi: 10.1007/s11910-017-0713-6.

Clinical Relevance of Steroid Use in Neuro-Oncology

Affiliations
Review

Clinical Relevance of Steroid Use in Neuro-Oncology

K Ina Ly et al. Curr Neurol Neurosci Rep. 2017 Jan.

Abstract

Background: Corticosteroids are commonly used in the management of primary central nervous system (CNS) tumors and CNS metastases to treat cancer- and treatment-related cerebral edema and improve neurologic function. However, they are also associated with significant morbidity and mortality, given their wide range of adverse effects.

Purpose of review: To review the mechanism of action, pharmacology, and toxicity profile of corticosteroids and to critically appraise the evidence that supports their use in neuro-oncologic practice based on the latest scientific and clinical data.

Recent findings: Recent data suggest that corticosteroids may negatively impact survival in glioma patients. In addition, corticosteroids should be incorporated as a standard criterion to assess a patient's clinical and radiographic response to treatment. Corticosteroids should be used judiciously in neuro-oncologic patients, given the potential deleterious effects on clinical outcome and patient survival. Anti-angiogenic agents, which lack these adverse effects, may be a reasonable alternative to corticosteroids.

Keywords: Brain metastases; Brain tumor; Cerebral edema; Corticosteroids; Response assessment; Steroids.

PubMed Disclaimer

References

    1. Ann Intern Med. 1974 Oct;81(4):505-12 - PubMed
    1. Neuro Oncol. 2015 Aug;17(8):1114-20 - PubMed
    1. Am J Med. 1994 Feb;96(2):115-23 - PubMed
    1. J Neurooncol. 2010 Jan;96(1):103-14 - PubMed
    1. J Neurooncol. 2010 Oct;100(1):89-94 - PubMed

MeSH terms

Substances

LinkOut - more resources